These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24842638)

  • 1. The ISoP Standards and Best Practices Committee.
    Bruno R; Mentré F; Tannenbaum S; Wang Y; Corrigan B; Mager DE
    Clin Pharmacol Ther; 2014 Jun; 95(6):581-2. PubMed ID: 24842638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Clin Pharmacol; 2015 Aug; 55(8):875-87. PubMed ID: 26148467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate modeling in pharmacometrics: General points for consideration.
    Sanghavi K; Ribbing J; Rogers JA; Ahmed MA; Karlsson MO; Holford N; Chasseloup E; Ahamadi M; Kowalski KG; Cole S; Kerwash E; Wade JR; Liu C; Wang Y; Trame MN; Zhu H; Wilkins JJ;
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):710-728. PubMed ID: 38566433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
    Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
    Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whither pharmacometrics?: present state and future choices.
    Vicini P; Smith BP
    Clin Pharmacol Ther; 2014 Jun; 95(6):567-71. PubMed ID: 24842634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):301-14. PubMed ID: 25925797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volterra series in pharmacokinetics and pharmacodynamics.
    Verotta D
    J Pharmacokinet Pharmacodyn; 2003 Oct; 30(5):337-62. PubMed ID: 14977164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.
    Ou YC; Lo A; Lee B; Liu P; Kimura K; Eary C; Hopkins A
    J Clin Pharmacol; 2013 Nov; 53(11):1112-20. PubMed ID: 23913679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditioning on certain random events associated with statistical variability in PK/PD.
    Beal SL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):213-43. PubMed ID: 16283533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized exposure-controlled trials; impact of randomization and analysis strategies.
    Karlsson KE; Grahnén A; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Sep; 64(3):266-77. PubMed ID: 17425629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative.
    Karatza E; Yakovleva T; Adams K; Rao GG; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2022 Aug; 49(4):397-400. PubMed ID: 35474412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.
    Farenc C; Fabreguette JR; Bressolle F
    Comput Biomed Res; 2000 Oct; 33(5):315-29. PubMed ID: 11017724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum.
    Holford N; Karlsson MO
    Clin Pharmacol Ther; 2007 Jul; 82(1):103-5. PubMed ID: 17495873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.